top stories

Mod­er­na CEO Stéphane Ban­cel out­lines a prospec­tive moth­er­lode of Covid-19 vac­cine rev­enue — will a back­lash fol­low?

2 hours ago
Coronavirus

UP­DAT­ED: No­vavax her­alds the lat­est pos­i­tive snap­shot of ear­ly-stage Covid-19 vac­cine — so why did its stock ...

19 hours ago
Coronavirus

Covid-19 roundup: J&J and BAR­DA agree to $1 bil­lion for 100 mil­lion dos­es; Plas­ma re­duces mor­tal­i­ty by 50% — ...

3 hours ago
Coronavirus

RA, No­var­tis back Gen­tiBio's seed round, plans to launch de­vel­op­ment of En­gTreg ther­a­pies

24 minutes ago
Venture

Latest

Most read

When will it end? Gold­man econ­o­mist gives late-stage vac­cines a good shot at tar­get­ing 'large shares' of the US by ...

Yesterday
R&D
Coronavirus

Stem cell play­er Vi­a­Cyte ex­pands col­lab­o­ra­tion with Gore to de­vel­op sub­cu­ta­neous di­a­betes treat­ment

39 minutes ago
Deals

Less than 3 months af­ter launch, the AveX­is crew’s Taysha rais­es $95M Se­ries B. Is an IPO next?

51 minutes ago
Venture
Startups

My­ovant lands a fresh $200M loan as FDA mar­ket­ing de­ci­sion looms; Amarin goes it alone in Eu­rope

56 minutes ago
Protocols

Ver­sant de­buts Ridge­line's start­up #4, armed with $30M and al­ter­na­tive TCR cell ther­a­pies for sol­id tu­mors

3 hours ago
Venture
Startups

CF Foun­da­tion, Long­wood team on new in­cu­ba­tor for com­pa­nies with cut­ting-edge CF treat­ments

4 hours ago
Venture
Cell/Gene Tx
see latest stream
People

Cure­Vac nabs a top No­var­tis sci­en­tist for CSO slot as mR­NA vac­cines seize the spot­light

Yesterday

Rich Hey­man joins PMV Phar­ma, a p53 biotech, as it adds $70 mil­lion in Se­ries D

2 days ago

CAR-T fil­ing in sight, Frank Zhang grabs full con­trol of J&J-part­nered Leg­end Biotech, steps down from Gen­Script

2 days ago
Startups

IgGenix emerges from stealth with $10 mil­lion Se­ries A hop­ing to re-en­gi­neer al­ler­gic cas­cade

Yesterday

'Ex­quis­ite con­trol': Flag­ship pulls off $85M ral­ly around Omega Ther­a­peu­tic­s' clin­i­cal push for epi­ge­net­ic ...

Last week

Three years af­ter leav­ing Bio­gen, Alp­na Seth takes the spot­light with $73M for her neu­ro start­up

Last week
Deals

Mer­ck scoops up a PhII J&J dis­card in a bar­gain-base­ment deal. And this time they’re shoot­ing at NASH

Yesterday

As­traZeneca throws Redx a life­line — in ex­change for a pre­clin­i­cal fi­bro­sis drug — with a promise of $17M in ...

Yesterday

Sanofi and GSK say they're near a vac­cine deal with EU hours af­ter fi­nal­iz­ing Warp Speed con­tract

4 days ago
IPOs

Days af­ter seal­ing Sanofi pact, Kymera beats a path to the Nas­daq with $100M IPO pitch

2 days ago

AlloVir rides IPO boom on first mar­ket day, soars af­ter bag­ging $276 mil­lion

5 days ago

In­hi­brx takes a sec­ond shot at an IPO — this time bump­ing the goal to $100M-plus

Last week

Premium storiesSee all

So Covid-19 leader BioN­Tech has a can­cer vac­cine in de­vel­op­ment? Yes, and Re­gen­eron just jumped in for the PhII com­bo ...

2 days ago
Bioregnum
R&D

Af­ter Big Phar­ma aban­doned in­fec­tious dis­eases, 5 biotech con­trar­i­ans de­cid­ed to go all in. Then Covid-19 changed ...

Last week
People
Coronavirus

A wob­bly Bio­gen makes a sur­prise switch in the ex­ec­u­tive suite, trig­ger­ing a re­newed burst of M&A chat­ter

2 weeks ago
People

Gilead lines up a $1.55B biotech buy­out deal as CEO Dan O’Day in­vests in his lat­est can­cer block­buster dream

3 weeks ago
Deals

Don't missSee all

OWS' Mon­cef Slaoui lam­basts ‘in­sult­ing’ me­dia cov­er­age: 'How are you help­ing in this pan­dem­ic?'

Yesterday
Coronavirus

J&J gets a fresh OK for es­ke­t­a­mine, but is it re­al­ly the game-chang­er for de­pres­sion Trump keeps tweet­ing about?

2 days ago
R&D
Regulatory

Trump’s ‘rad­i­cal’, ‘hor­ri­ble’ ex­ec­u­tive or­ders on drug pric­ing earn a C-suite back­lash this week — with ...

5 days ago
People
Bioregnum

Brigham and Wom­en's pres­i­dent Eliz­a­beth Nabel fol­lows Mon­cef Slaoui off Mod­er­na's board

5 days ago
People
Coronavirus

Endpoints Standouts

The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers

4 months ago
People
Special

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

7 months ago
Special
Pharma

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

8 months ago
People
R&D

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

9 months ago

Peer review See all

Jul
31

Tetraphase deal done, La Jol­la Phar­ma­ceu­ti­cal taps Lar­ry Ed­wards as CEO; Long­time Eli Lil­ly ex­ec Michael Over­dorf ...

Jul
24

Jeff Capel­lo out the door as Michael Mc­Don­nell takes over Bio­gen's CFO post; Ron Bruehlman named in­ter­im CFO at IQVIA

Jul
24

Turn­ing can­cer in­to a cur­able dis­ease: Im­munother­a­py ex­pert John Con­nol­ly picks up the reins as the new CSO of Sean ...

Jul
17

Tony Kings­ley takes over the reins at Schol­ar Rock; Idor­sia taps phar­ma vet Pa­tri­cia Torr for new US ops

Jul
10

Bob Goeltz bolts Uni­ty Biotech­nol­o­gy to be­come CFO at Ar­cus Bio­sciences; John John­son tapped for his lat­est CEO gig

R&D channel feed

2 days ago

FDA hands Mor­phoSys and In­cyte a quick OK on their po­ten­tial block­buster CAR-T al­ter­na­tive

Near­ly three years af­ter okay­ing the CAR-Ts Yescar­ta and Kym­ri­ah, the FDA has ap­proved a new CD19 ther­a­py. Mor­phoSys’ Mon­ju­vi, or taf­a­sita­m­ab-cx­ix, was cleared Fri­day for use in ...

READ MORE

No­var­tis says Kym­ri­ah reach­es pri­ma­ry end­point in new PhII, al­though num­bers still to come

Yesterday

Ab­b­Vie shrugs off $134M cash deals, quit­ting a neu­ro R&D pact with Voy­ager Ther­a­peu­tics on vec­tor­ized an­ti­body ...

Yesterday
latest in R&D

CymaBay flash­es pos­i­tive re­sults from the tri­al they have to re­launch

2 days ago

Im­mu­nic's lead MS drug hits pri­ma­ry and key sec­ondary end­points in PhII, but ques­tions re­main

2 days ago

Roche snags an FDA ap­proval for an ad­vanced melanoma drug cock­tail — but it's up against some fierce com­pe­ti­tion

5 days ago
Regulatory

Lex­i­con bids farewell to top sell­er Xer­me­lo in re­or­ga­ni­za­tion to­ward R&D pipeline

6 days ago
Deals

The lead drug in Alex­ion’s $930M buy­out deal last fall just flopped — adding in­jury to an­a­lysts’ M&A in­sults

6 days ago
Deals
see latest stories

Pharma channel feed

2 days ago

Sev­en plucky di­ag­nos­tics com­pa­nies win a $249M round of con­tracts af­ter sur­viv­ing NI­H's Covid-19 'Shark Tank' com­pe­ti­tion

As US Covid-19 deaths creep past 150,000 and of­fi­cials stress the im­por­tance of con­tact trac­ing, the NI­H's Rapid Ac­cel­er­a­tion of Di­ag­nos­tics (RADx) pro­gram has inked con­tracts to­tal­ing ...

READ MORE

Bio­gen's last-ditch pitch for an in­junc­tion to pro­tect Tec­fidera is de­nied, paving way for My­lan gener­ic

5 days ago

Genen­tech slash­es near­ly 500 jobs in strate­gic shift to 'lo­cal health­care ecosys­tems.' Clin­i­cal spe­cial­ists make up ...

6 days ago
R&D
latest in Pharma

Mod­er­na, Pfiz­er be­gin to give glimpse of Covid-19 vac­cine pric­ing — and prof­its

6 days ago
Coronavirus

Af­ter down year, 2020 brings new cash in­to Mass­a­chu­setts biotech

Last week
Venture

Trump looks to ham­mer down drug prices with 4 ex­ec­u­tive or­ders

Last week

So­bi's high-pri­or­i­ty rare dis­ease drug runs in­to a wall at EMA

Last week
Regulatory

Could a patent rul­ing threat­en Mod­er­na’s Covid-19 vac­cine?

Last week
see latest stories

Coronavirus channel feed

2 days ago

Covid-19 roundup: Eli Lil­ly retro­fits RVs for first-of-its-kind an­ti­body tri­al with NIH; Am­gen, Ab­b­Vie, Take­da team on a drug

Eli Lil­ly and the NIH are about to start a first-of-its-kind tri­al that re­searchers and de­vel­op­ers have talked about for months as a way of pro­vid­ing tem­po­rary im­mu­ni­ty to the most at-risk ...

READ MORE

Covid-19 roundup: FDA com­mis­sion­ers call for more ‘con­cert­ed ef­fort’ on con­va­les­cent plas­ma R&D; Re­gen­eron boosts ...

Yesterday

FDA touts ad­vanced man­u­fac­tur­ing to ad­dress Covid-19 short­falls

4 hours ago
Regulatory
latest in Coronavirus

Covid-19 roundup: Roger Perl­mut­ter hus­tles up hu­man vac­cine tri­als as Mer­ck looks to catch up on Covid-19; Chi­na hacked Mod­er­na, per of­fi­cial

5 days ago

Sanofi and GSK grab largest Warp Speed deal yet, se­cur­ing $2.1B for a vac­cine that might come next year

5 days ago

Covid-19 roundup: J&J gives deep­est look yet at vac­cine; As­traZeneca shies away from dis­cussing vac­cine com­mer­cial op­por­tu­ni­ty

6 days ago

Covid-19 roundup: Mod­er­na re­moved signs around its man­u­fac­tur­ing plant — is it a tar­get for hack­ers?

Last week

Roche de­clares a PhI­II fail­ure for Covid-19 as the IL-6 re­pur­pos­ing the­o­ry bites the dust

Last week
R&D
see latest stories